SCM
SAGE

Segantii Capital Management’s Sage Therapeutics SAGE Stock Holding History

Segantii Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-200
Closed -$14K – 221
2017
Q1 		$14K Buy
+200
New +$11.7K ﹤0.01% 364

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Segantii Capital Management's SAGE Position: Q2 2017 in Review

Segantii Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2017, closing a stake of 200 shares — an estimated $14K sold.

Segantii Capital Management first reported a position in SAGE in Q1 2017 and held it in 1 quarter. The position peaked at $14K in Q1 2017. 190 funds tracked by Wall St. Rank hold SAGE as of Q2 2017.

  • Segantii Capital Management reported no remaining Sage Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 200 Sage Therapeutics shares in Q2 2017, an estimated $14K.
  • Segantii Capital Management first reported a position in Sage Therapeutics in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Sage Therapeutics position peaked at $14K in Q1 2017.
  • 190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.